Targeted pharmaceutical nanocarriers for cancer therapy and imaging

By Vladimir Torchilin. AAPS Journal, 2007

744 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A review of stimuli-responsive nanocarriers for drug and gene delivery. (2008, background): “Different types of stimu delivered to desired sub-cellular compartments in an efficient and reproducible manner [2].”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “For more information on lipid core micelles, please see Lukyanov and Torchilin (2004) and Torchilin (2007a).”
Current trends in the use of liposomes for tumor targeting (2013, background): “Prolonged systemic circulation allows longer interaction of liposomes with the target because the higher number of passages of blood through the target enhances the EPR effect [15].”
Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery (2017, methodology): “In another typical example, a multifunctional nanocarrier with PEGylated TATp-modified pH-sensitive liposomes was designed in which pH-labile hydrazone bond was inserted between PEG and PE (PEG-Hz-PE) (Sawant et al., 2006; Kale & Torchilin, 2007b).”